Ikena Oncology, Inc. - Common Stock (IKNA)

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function

Strong financial position with $138 million in cash and investments at close of third quarter

Strong financial position with $145 million in cash and investments at close of second quarter

Ikena to discontinue development of IK-930

Ikena to discontinue development of IK-930

Strong financial position with $157.3 million; runway into 2H 2026

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event.

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024, in Boston, MA. The Company will also be holding one-on-one investor meetings at the conference.

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November.

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY.

Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023

Ikena receives approximately $43 million in net cash at closing

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in TD Cowen’s 4th Annual Oncology Innovation Summit taking place May 30-31, 2023, and the Jefferies Healthcare Conference taking place June 7-9, 2023.

Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of common stock (the “Shares”) at an offering price of $6.55 per share. The gross proceeds to the Company, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $40 million. The offering is expected to close on or about May 17, 2023, subject to satisfaction of customary closing conditions. The Company anticipates the net proceeds of the offering, together with existing cash, cash equivalents and investments, to further its ongoing clinical development of targeted oncology programs and advance them to clinical data read outs beyond the initial data for the monotherapy portion of the ongoing IK-930 Phase 1 clinical trial in the fourth quarter of 2023 and initial clinical data for IK-595, in addition to working capital, capital expenditures and other general corporate purposes. The financing was co-led by a new healthcare dedicated investor and included additional new investors, Acuta Capital Partners, Adage Capital, and Vestal Point Capital, as well as participation from existing investors.

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in one-on-one investor meetings at the Stifel 2023 Virtual Targeted Oncology Days, taking place April 25-26, 2023.

IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling

Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the Company is presenting preclinical data on its newest program in next-generation MEK-RAF inhibition, IK-595, at the American Association for Cancer Research (AACR) Special Conference: Targeting RAS, taking place this week in both a poster presentation and a plenary session talk.

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Company’s novel aryl hydrocarbon receptor (AHR) antagonist, in combination with immune checkpoint inhibitors in patients with advanced urothelial carcinoma who have progressed on or within three months of receiving the last dose of checkpoint inhibitors.

BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a Targeted Oncology Panel at the Cowen 43rd Annual Health Care Conference, taking place March 6-8, 2023 in Boston, MA. The Company will also be holding investor meetings at the conference.